Lumos Pharma, Inc. (LUMO)
Dec 12, 2024 - LUMO was delisted (reason: acquired by Double Point Ventures)
4.340
0.00 (0.00%)
Inactive · Last trade price
on Dec 11, 2024
Lumos Pharma Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2017 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '24 Sep 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2017 |
| Revenue | 2.21 | 2.05 | 1.52 | 0.23 | 0.17 | - | Upgrade
|
| Revenue Growth (YoY) | 26.94% | 34.67% | 562.17% | 36.90% | - | - | Upgrade
|
| Gross Profit | 2.21 | 2.05 | 1.52 | 0.23 | 0.17 | - | Upgrade
|
| Selling, General & Admin | 15.85 | 16.57 | 15.71 | 15.33 | 17.27 | 4.15 | Upgrade
|
| Research & Development | 22.69 | 22.1 | 17.86 | 16.25 | 9.21 | 5.67 | Upgrade
|
| Operating Expenses | 38.53 | 38.67 | 33.56 | 31.58 | 26.47 | 9.82 | Upgrade
|
| Operating Income | -36.33 | -36.61 | -32.04 | -31.35 | -26.3 | -9.82 | Upgrade
|
| Interest & Investment Income | 1.14 | 1.87 | 0.87 | 0.01 | 0.2 | 0.07 | Upgrade
|
| Other Non Operating Income (Expenses) | 0.27 | 0.68 | 0.09 | 0.27 | 0.17 | 0.04 | Upgrade
|
| EBT Excluding Unusual Items | -34.92 | -34.06 | -31.08 | -31.07 | -25.94 | -9.71 | Upgrade
|
| Gain (Loss) on Sale of Assets | - | - | - | - | 6.3 | - | Upgrade
|
| Pretax Income | -34.92 | -34.06 | -31.08 | -31.07 | -19.64 | -9.71 | Upgrade
|
| Income Tax Expense | - | -0.03 | -0.01 | -0.64 | -13.97 | - | Upgrade
|
| Net Income | -34.92 | -34.03 | -31.06 | -30.43 | -5.66 | -9.71 | Upgrade
|
| Preferred Dividends & Other Adjustments | - | - | - | - | 0.65 | 3.04 | Upgrade
|
| Net Income to Common | -34.92 | -34.03 | -31.06 | -30.43 | -6.31 | -12.75 | Upgrade
|
| Shares Outstanding (Basic) | 8 | 8 | 8 | 8 | 7 | 8 | Upgrade
|
| Shares Outstanding (Diluted) | 8 | 8 | 8 | 8 | 7 | 8 | Upgrade
|
| Shares Change (YoY) | -0.71% | -2.73% | 0.47% | 22.97% | -11.44% | -25.58% | Upgrade
|
| EPS (Basic) | -4.28 | -4.18 | -3.71 | -3.65 | -0.93 | -1.67 | Upgrade
|
| EPS (Diluted) | -4.28 | -4.18 | -3.71 | -3.65 | -0.93 | -1.67 | Upgrade
|
| Free Cash Flow | -31.67 | -31.1 | -26.64 | -29.68 | -23.03 | -9.09 | Upgrade
|
| Free Cash Flow Per Share | -3.88 | -3.82 | -3.18 | -3.56 | -3.40 | -1.19 | Upgrade
|
| Gross Margin | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | - | Upgrade
|
| Operating Margin | -1647.57% | -1785.18% | -2103.74% | -13629.13% | -15656.55% | - | Upgrade
|
| Profit Margin | -1583.49% | -1659.39% | -2039.53% | -13230.43% | -3758.33% | - | Upgrade
|
| Free Cash Flow Margin | -1436.42% | -1516.09% | -1749.44% | -12903.48% | -13706.55% | - | Upgrade
|
| EBITDA | -36.31 | -36.57 | -31.99 | -31.13 | -25.72 | -9.78 | Upgrade
|
| D&A For EBITDA | 0.02 | 0.04 | 0.05 | 0.22 | 0.58 | 0.04 | Upgrade
|
| EBIT | -36.33 | -36.61 | -32.04 | -31.35 | -26.3 | -9.82 | Upgrade
|
| Revenue as Reported | 2.21 | 2.05 | 1.52 | 0.23 | 0.17 | - | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.